Table 1 Characteristics of HCQ-treated SLE patients
Patient characteristics (n = 26) | |
|---|---|
Females, n (%) | 21 (81) |
Age years, median (range) | 49.5 (20–79) |
Disease duration years, median (range) | 10.5 (1–30) |
Number of ACR criteria, median (range) | 5 (4–9) |
Number of SLICC criteria, median (range) | 7 (4–12) |
SLICC/ACR damage index, median (range) | 0 (0–4) |
SLEDAI at blood sampling, median (range) | 2 (0–18) |
Creatinine (μmol/L), median (range) | 70 (41–178) |
Alanine aminotransferase (μkat/L), median (range) | 0.43 (0.16–0.87) |
BMIa, median (range) | 25 (18.4–35.3) |
HCQ dose 2800 mg/week, n (%) | 2 (8) |
HCQ dose 1800–2000 mg/week, n (%) | 9 (35) |
HCQ dose 1400 mg/week, n (%) | 14 (54) |
HCQ dose 0 mg/week, n (%) | 1 (4) |
Prednisone dose, mg/day median (range) | 1.25 (0–25) |
Azathioprine, n (%) | 7 (29) |
Mycophenolate mofetil, n (%) | 2 (8) |
Methotrexate, n (%) | 2 (8) |
Intravenous immunoglobulins, n (%) | 2 (8) |
Rituximab, n (%) | 2 (8) |
Belimumab, n (%) | 1 (4) |
No other DMARDs, n (%) | 11 (42) |